John Castello, chairman, president and CEO of Xoma commented, “Although Zephyr has devoted both time and effort toward the advancement of BPI, they have not met the financing requirements of our agreement and this led to our decision to terminate the relationship”.
“BPI’s excellent safety profile continues to be an attractive feature in clinical use as evidenced by its ongoing evaluation in both pediatric and adult indications, Xoma remains committed to the future development of BPI and is actively seeking new partnerships with private and public companies.”
BPI (bactericidal/permeability-increasing protein), a human protein found in certain white blood cells (neutrophils), is one of the body’s natural defenses against bacterial infections.